Colin B, Baignet, BM
University of Oxford, Oxford, United Kingdom
SHARP, Study of Heart and Renal Protection
Oscar Benavente, MD
University of Texas Health Science Center, San Antonio, TX
SPS3, Secondary Prevention of Small Subcortical Strokes
Merit Cudkowicz, MD
Massachusetts General Hospital/Harvard Medical School, Boston, MA
Celebrex in ALS
Hertzel Gerstein, MD
Professor of Medicine and Chief of Division of Endocrinology
McMaster University Faculty of Health Sciences
Hamilton, Ontario, Canada
ORIGIN, Outcome Reduction with Initial Glargine Intervention (Co-principal Investigator)
DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone
Medication (Co-principal Investigator)
Charles H. Hennekens, MD, DrPh
Mount Sinai Medical Center
TACT, Trial to Assess Chelation Therapy (Co-principal Investigator)
Gervasio A. Lamas, MD
Mount Sinai Medical Center
TACT, Trial to Assess Chelation Therapy (Co-principal Investigator) |
|
Martin Landray, BM
University of Oxford, Oxford, United Kingdom
SHARP, Study of Heart and Renal Protection
Jeffery Probstfield, MD
University of Washington School of Medicine
ORIGIN, Outcome Reduction with Initial Glargine Intervention (Principal Investigator for U.S. Regional Coordinating Center)
Eric Sorenson, MD
Mayo Clinic, Rochester, MN
IGF-I (Myotrophin) in ALS
Salim Yusuf, MD
Professor of Medicine and Chief of Division of Cardiology
McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
ORIGIN, Outcome Reduction with Initial Glargine Intervention (Co-principal Investigator)
DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone
Medication (Co-principal Investigator)
ONTARGET/TRANSCEND
OnTarget: Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial: A large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events
Transcend: Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease
Robert Byington, PhD
Wake Forest School of Medicine, Winston-Salem, NC ACCORD, Action to Control Cardiovascular Risks in Diabetes
John McNeil, PhD, MSc
Monash University, Melbourne, Australia ASPREE, ASPirin in Reducing Events in the Elderly |